Know Cancer

or
forgot password

Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma


Phase 2
18 Years
N/A
Not Enrolling
Both
Thyroid Neoplasms

Thank you

Trial Information

Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma


Inclusion Criteria:



- 18 -75 years

- Karnofsky ≥ 70%

- Histological diagnosis of medullary thyroid carcinoma

- Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years

- Normal liver and renal functions

- Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3

- No immunization

- Consent form signed

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Francoise Bodere, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

CHU de Nantes

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

BRD 03/2-U

NCT ID:

NCT00467506

Start Date:

May 2004

Completion Date:

January 2011

Related Keywords:

  • Thyroid Neoplasms
  • Recurrence of medullary thyroid carcinoma: abnormal calcitonin level and biomarkers doubling time lower than 5 years after initial surgery
  • Neoplasms
  • Carcinoma
  • Thyroid Neoplasms
  • Thyroid Diseases

Name

Location